Boosting regulatory T cell-dependent immune tolerance by activation of p53

Regulatory T cells (Tregs) have critical roles in maintaining immune hemostasis and have important antiinflammatory functions in diseases. Recently, we identified that CX-5461 (a selective RNA polymerase I inhibitor and p53 activator) acted as a potent immunosuppressive agent, which prevented allogeneic acute rejection in animal models via a molecular mechanism distinct from all those of conventional immunosuppressive drugs. Unexpectedly, we discovered that CX-5461 could promote Treg differentiation. In this review, we have summarized the evidence for a potential role of p53 in mediating Treg differentiation and its possible mechanisms, including regulation of FoxP3 transcription, regulation of the expression of PTEN (phosphatase and tensin homolog), as well as protein-protein interaction with the transcription factor STAT5 (signal transducer and activator of transcription 5). Evidence also suggests that pharmacological p53 activators may potentially be used to boost Treg-mediated immune tolerance. Based on these data, we argue that novel p53 activators such as CX-5461 may represent a distinct class of immunosuppressants that repress conventional T cell-mediated alloimmunity with concomitant boosting of Treg-dependent immune tolerance.

Automated summary

Regulatory T cells (Tregs) play critical roles in immune balance and anti-inflammatory responses. Recent studies have shown that CX-5461 can promote Treg differentiation and prevent allogeneic acute rejection through a unique molecular mechanism. These findings suggest a potential role of p53 in mediating Treg differentiation and regulating Treg function through various mechanisms. Pharmacological p53 activators may offer new possibilities for enhancing Treg-mediated immune tolerance.